8-K - CAMP4 Therapeutics Corporation | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

CAMP4 Therapeutics Corporation appointed Michael MacLean as a Class III director effective April 1, 2026, increasing the Board size from eight to nine members. He was also appointed to the Audit Committee and Compensation Committee, and will receive an option to purchase 56,000 shares of common stock vesting monthly over three years under the amended Non-Employee Director Compensation Policy.

Key Takeaways

1Board appointed Michael MacLean, age 60, as Class III director effective 2026-04-01.

2Board size increased from 8 to 9 members on March 18, 2026.

3Mr. MacLean appointed to Audit Committee and Compensation Committee effective 2026-04-01.

4Granted option for 56,000 shares under 2024 Equity Incentive Plan, vesting monthly over 3 years.

5Amended Non-Employee Director Compensation Policy for new directors on or after 2026-04-01.

Current Report Details

Event Type

Management Change

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 18,

Management Change

Executive & Director Changes

Michael MacLean

Class III director, Audit Committee, Compensation Committee

appointed

Effective: 2026-04-01

Exhibits (1)

8-K